Quintiles' PGx Focus Continues with London Genetics Personalized Medicine Alliance
November 30, 2010
Quintiles' PGx Focus Continues with London Genetics Personalized Medicine Alliance
After inking a similar deal with Dako earlier in the month, Quintiles announced this week that it would collaborate with pharmacogenetics firm London Genetics to provide personalized medicine services to drug developers. Financial terms of the deal were not disclosed.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In Latest PGx Pact with Population Genetics, Quintiles Hopes to Save Pharma Money and Time
May 25, 2011 / Pharmacogenomics Reporter - Dako, Quintiles Partner on Personalized Rx; First Project to Focus on AstraZeneca Cancer Rx
November 3, 2010 / Pharmacogenomics Reporter - Dako, Quintiles Ink Personalized Medicine Alliance
November 1, 2010 / GenomeWeb Daily News - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Quintiles, London Genetics Ink PGx Services Pact
November 29, 2010 / GenomeWeb Daily News